IMMUNITYBIO INC (IBRX)

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

/PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform...

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the...

ImmunityBio Reports Third-Quarter 2024 Financial Results

Commit To Buy ImmunityBio At $4, Earn 25% Using Options

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Notable Friday Option Activity: IBRX, EVLV, CRI

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Notable Monday Option Activity: ROKU, FLR, IBRX

Noteworthy Friday Option Activity: TGT, IBRX, UDMY

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Noteworthy Monday Option Activity: IBRX, TGTX, NTNX

IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024

IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ImmunityBio (NASDAQ:IBRX) just reported results for the second quarter of 2024....

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio is Now Oversold (IBRX)

IBRX Makes Notable Cross Below Critical Moving Average

IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX)...

7 Biotech Stocks to Keep on Your Clinical Radar

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Notable Wednesday Option Activity: MU, CRWD, IBRX

3 Top Cancer Treatment Stocks to Buy Now

These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.